NOTE 5 - DEFERRED R&D OBLIGATIONS - PARTICIPATION AGREEMENTS

In the three months ended March 31, 2023 and 2022, the Company recognized $125,030 and $136,848 as a contra R&D expense related to personnel and third-party expenses to develop the subject technology, respectively. For the three months ended March 31, 2023, $31,274 of this total contra R&D expense was attributed to deferred R&D obligations funded by a related party.